Literature DB >> 9147877

Fanconi anemia complementation group E: clinical and cytogenetic data of the first patient.

R D Wegner1, I Henrichs, H Joenje, T Schroeder-Kurth.   

Abstract

The clinical and cytogenetic data of the first patient proven to belong to the fifth Fanconi anemia complementation group are described. The Turkish boy presented with psychomotoric retardation, growth retardation, retarded bone age, brachycephaly, hypotelorism, epicanthus, syndactyly, brachydactyly, renal dystopia, and cryptorchism. In addition, an asymmetrical skeletal anomaly was seen with a double distal phalanx of the left thumb and hypoplasia of the right thumb. Typical hematological features of the disorder developed, at the age of 2.5 years, about 1 year after diagnosis. Cytogenetic studies confirmed the clinical diagnosis and revealed a spontaneous chromosomal instability and hypersensitivity to the cross-linking agents diepoxybutane and Trenimon. The findings in the patient, who is considered to be the standard for the fifth Fanconi anemia complementation group, are compared with data reported for other patients affected with Fanconi anemia.

Entities:  

Mesh:

Year:  1996        PMID: 9147877     DOI: 10.1111/j.1399-0004.1996.tb02716.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  2 in total

1.  The Fanconi anemia group E gene, FANCE, maps to chromosome 6p.

Authors:  Q Waisfisz; K Saar; N V Morgan; C Altay; P A Leegwater; J P de Winter; K Komatsu; G R Evans; R D Wegner; A Reis; H Joenje; F Arwert; C G Mathew; J C Pronk; M Digweed
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

Review 2.  The causes of Fanconi anemia in South Asia and the Middle East: A case series and review of the literature.

Authors:  Ashley S Thompson; Nusrat Saba; Lisa J McReynolds; Saeeda Munir; Parvez Ahmed; Sumaira Sajjad; Kristine Jones; Meredith Yeager; Frank X Donovan; Settara C Chandrasekharappa; Blanche P Alter; Sharon A Savage; Sadia Rehman
Journal:  Mol Genet Genomic Med       Date:  2021-05-07       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.